<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35244">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02015520</url>
  </required_header>
  <id_info>
    <org_study_id>IM133-066</org_study_id>
    <secondary_id>2013-003780-65</secondary_id>
    <nct_id>NCT02015520</nct_id>
  </id_info>
  <brief_title>Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Italy: National Bioethics Committee</authority>
    <authority>Italy: National Institute of Health</authority>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to identify an appropriate dose of study medication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) change from baseline at Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) 20/50/70 Responses</measure>
    <time_frame>At week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>At week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>At week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boolean Remission</measure>
    <time_frame>At week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health assessment questionnaire disability index (HAQ-DI) change from baseline at Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28- Erythrocyte sedimentation rate (ESR) &lt;2.6</measure>
    <time_frame>At week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28-CRP&lt;2.6</measure>
    <time_frame>At week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on adverse events (AEs), vital signs, physical examinations, safety lab values and immunogenicity during the double-blind period</measure>
    <time_frame>Up to week 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Clazakizumab (Dose # A) (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Clazakizumab (Dose # B) (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Clazakizumab (Dose # C) (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Placebo matching with Clazakizumab (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Clazakizumab (Dose# A) (Open Label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any subject who completes Double-Blind will receive Clazakizumab Dose # A injection by subcutaneous + background Methotrexate for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clazakizumab</intervention_name>
    <arm_group_label>Arm 1: Clazakizumab (Dose # A) (Double-Blind)</arm_group_label>
    <arm_group_label>Arm 2: Clazakizumab (Dose # B) (Double-Blind)</arm_group_label>
    <arm_group_label>Arm 3: Clazakizumab (Dose # C) (Double-Blind)</arm_group_label>
    <arm_group_label>Arm 5: Clazakizumab (Dose# A) (Open Label)</arm_group_label>
    <other_name>BMS-945429</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Matching with Clazakizumab)</intervention_name>
    <arm_group_label>Arm 4: Placebo matching with Clazakizumab (Double-Blind)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American
             Rheumatism association (ARA) [1987] or American College of Rheumatology/European
             League Against Rheumatism (ACR/EULAR) [2010]) at least 16 weeks prior to screening

          -  ACR global functional status class of 1 to 3

          -  Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors

          -  All subjects must have been receiving treatment with a minimum dose of 15 mg per week
             of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to
             screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be
             reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per
             week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is
             permitted, if it is at a dose approved for the treatment of RA and the dose has been
             stable for at least 28 days prior to screening

          -  Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at
             baseline (Day 1)

          -  Elevated High-sensitivity (hs) CRP

        Exclusion Criteria:

          -  Active serious infection

          -  History of or active tuberculosis (TB)

          -  Elevated liver function tests (LFTs)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rheumatology Associates Of North Alabama, P.C.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Shergy, Site 0013</last_name>
      <phone>256-265-6778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Hot Springs Communities</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody D St. John, Site 0014</last_name>
      <phone>501-622-4175</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valerius Med Group &amp; Res Ctr Of Greater Long Beach, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathaniel Neal, Site 0012</last_name>
      <phone>562-989-2374</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Greenwald, Site 0018</last_name>
      <phone>760-341-6800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarasota Arthritis Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Kaine, Site 0020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Birbara, Site 0008</last_name>
      <phone>508-752-1824</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0057</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, Llc</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melvin Churchill, Site 0021</last_name>
      <phone>402-420-1212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0054</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0060</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0063</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Physicians East, Pa</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey  A Alloway, Site 0046</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting, Llc</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isam A Diab, Site 0017</last_name>
      <phone>440-826-0742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Research Of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Codding, Site 0009</last_name>
      <phone>405-702-6770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0055</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Consultants Pllc</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Gornisiewicz, Site 0010</last_name>
      <phone>865-602-7983</phone>
      <phone_ext>230</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>1878</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0032</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0024</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1121</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0036</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0034</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0053</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0042</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0047</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0039</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0040</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0041</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0045</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0056</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0038</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0033</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>2608712</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>8078555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kato-shi</city>
        <state>Hyogo</state>
        <zip>6731462</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagano-shi</city>
        <state>Nagano</state>
        <zip>3808582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sasebo-shi</city>
        <state>Nagasaki</state>
        <zip>8571165</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>1708476</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nishimuro-gun</city>
        <state>Wakayama</state>
        <zip>6492211</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0059</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0030</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0029</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0031</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
